Amedeo Smart

Free Medical Literature Service

 

Amedeo

Ovarian Neoplasms
  Free Subscription

Articles published in
Ann Oncol
    October 2025
  1. KRISTELEIT RS, Ghamande S, Lisyanskaya A, Oaknin A, et al
    Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45.
    Ann Oncol. 2025 Oct 18:S0923-7534(25)04950-6. doi: 10.1016/j.annonc.2025.
    >> Share

    August 2025
  2. RAY-COQUARD I, Cropet C, Harter P, Pujade-Lauraine E, et al
    Reply to Letter to the Editor "Long-term follow-up of PAOLA-1 and the evolving landscape of post-PARP treatment strategies in ovarian cancer" by Arenhardt and Nogueira-Rodrigues.
    Ann Oncol. 2025 Aug 4:S0923-7534(25)00832-4. doi: 10.1016/j.annonc.2025.
    >> Share

    July 2025
  3. ARENHARDT MP, Nogueira-Rodrigues A
    Re: Long-term follow-up of PAOLA-1 and the evolving landscape of post-PARP treatment strategies in ovarian cancer.
    Ann Oncol. 2025 Jul 7:S0923-7534(25)00831-2. doi: 10.1016/j.annonc.2025.
    >> Share

    May 2025
  4. HARDY-BESSARD AC, Pujade-Lauraine E, Moore RG, Montestruc F, et al
    Dostarlimab and niraparib in primary advanced ovarian cancer.
    Ann Oncol. 2025 May 30:S0923-7534(25)00201-7. doi: 10.1016/j.annonc.2025.
    >> Share

    March 2025
  5. CHAMBERS LM, Eskander RN, O'Malley DM
    Targeting the future: Antibody-Drug Conjugates (ADCs) in platinum-sensitive ovarian cancer in the post-PARP era.
    Ann Oncol. 2025;36:244-246.
    >> Share

    November 2024
  6. SECORD AA, Lewin SN, Murphy CG, Cecere SC, et al
    The Efficacy and Safety of Mirvetuximab Soravtansine in FRalpha-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial.
    Ann Oncol. 2024 Nov 29:S0923-7534(24)04948-2. doi: 10.1016/j.annonc.2024.
    >> Share

  7. HARTER P, Marth C, Mouret-Reynier MA, Cropet C, et al
    Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.
    Ann Oncol. 2024 Nov 9:S0923-7534(24)04907-X. doi: 10.1016/j.annonc.2024.
    >> Share

    September 2024
  8. MONK BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, et al
    Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
    Ann Oncol. 2024 Sep 14:S0923-7534(24)03762-1. doi: 10.1016/j.annonc.2024.08.2241
    >> Share

    January 2024
  9. LEDERMANN JA, Matias-Guiu X, Amant F, Concin N, et al
    ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.
    Ann Oncol. 2024 Jan 29:S0923-7534(23)05103-7. doi: 10.1016/j.annonc.2023.
    >> Share

    December 2023
  10. MCNEISH IA, Monk BJ
    Is more of a good thing still a good thing? PARP inhibitor retreatment in high-grade ovarian carcinoma.
    Ann Oncol. 2023;34:1074-1076.
    >> Share

    October 2023
  11. SESSA C, Paluch-Shimon S
    Reply to the Letter to the Editor 'There is no place for ovarian cancer screening in hereditary breast-ovarian cancer syndromes (in regard to "ESMO Clinical Practice Guideline on risk reduction and screening of cancer in hereditary breast-ovarian canc
    Ann Oncol. 2023 Oct 26:S0923-7534(23)04325-9. doi: 10.1016/j.annonc.2023.
    >> Share

  12. TJALMA WAA
    There is no place for ovarian cancer screening in hereditary breast-ovarian cancer syndromes.
    Ann Oncol. 2023 Oct 20:S0923-7534(23)04324-7. doi: 10.1016/j.annonc.2023.
    >> Share

  13. PUJADE-LAURAINE E, Selle F, Scambia G, Asselain B, et al
    Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.
    Ann Oncol. 2023 Oct 3:S0923-7534(23)04007-3. doi: 10.1016/j.annonc.2023.09.3110.
    >> Share

    August 2023
  14. GONZALEZ-MARTIN A, Harter P, Leary A, Lorusso D, et al
    Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
    Ann Oncol. 2023 Aug 10:S0923-7534(23)00797-4. doi: 10.1016/j.annonc.2023.
    >> Share

    May 2023
  15. RAY-COQUARD I, Leary A, Pignata S, Cropet C, et al
    Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
    Ann Oncol. 2023 May 19:S0923-7534(23)00686-5. doi: 10.1016/j.annonc.2023.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016